[go: up one dir, main page]

WO2002055544A2 - Fractions de fixation de la fibrine qui conviennent comme agents d'imagerie - Google Patents

Fractions de fixation de la fibrine qui conviennent comme agents d'imagerie Download PDF

Info

Publication number
WO2002055544A2
WO2002055544A2 PCT/US2001/049534 US0149534W WO02055544A2 WO 2002055544 A2 WO2002055544 A2 WO 2002055544A2 US 0149534 W US0149534 W US 0149534W WO 02055544 A2 WO02055544 A2 WO 02055544A2
Authority
WO
WIPO (PCT)
Prior art keywords
cys
gly
pro
trp
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/049534
Other languages
English (en)
Other versions
WO2002055544A3 (fr
Inventor
Charles R Wescott
James P Beltzer
Aaron K Sato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dyax Corp
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Priority to AU2002248222A priority Critical patent/AU2002248222B2/en
Priority to CA2432474A priority patent/CA2432474C/fr
Priority to EP01997103A priority patent/EP1348026A2/fr
Priority to JP2002556612A priority patent/JP3991086B2/ja
Publication of WO2002055544A2 publication Critical patent/WO2002055544A2/fr
Publication of WO2002055544A3 publication Critical patent/WO2002055544A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des fractions de fixation de la fibrine qui possèdent diverses utilisations, que ce soit dans la détection, dans l'isolation ou dans la localisation de la fibrine, et plus particulièrement la fibrine en tant qu'opposé au fibrinogène, est intéressante. Cette invention concerne particulièrement des polypeptides isolés synthétiques capables de se fixer à la fibrine et de reconnaître la forme de la fibrine polymérisée trouvée dans les thrombi. Par ailleurs, ces polypeptides possèdent une vitesse de dissociation des thrombi faible, ce qui améliore leur capacité de former une image de contraste au niveau d'un site de caillot de fibrine et rend ces fractions de fixation particulièrement utiles comme agents d'imagerie pour les thrombi.
PCT/US2001/049534 2000-12-23 2001-12-21 Fractions de fixation de la fibrine qui conviennent comme agents d'imagerie Ceased WO2002055544A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002248222A AU2002248222B2 (en) 2000-12-23 2001-12-21 Fibrin binding polypeptides useful inter alia in medical imaging processes
CA2432474A CA2432474C (fr) 2000-12-23 2001-12-21 Fractions de fixation de la fibrine qui conviennent comme agents d'imagerie
EP01997103A EP1348026A2 (fr) 2000-12-23 2001-12-21 Fractions de fixation de la fibrine qui conviennent comme agents d'imagerie
JP2002556612A JP3991086B2 (ja) 2000-12-23 2001-12-21 造影剤として有用なフィブリン結合部分

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74740300A 2000-12-23 2000-12-23
US09/747,403 2000-12-23

Publications (2)

Publication Number Publication Date
WO2002055544A2 true WO2002055544A2 (fr) 2002-07-18
WO2002055544A3 WO2002055544A3 (fr) 2003-03-27

Family

ID=25004908

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/049534 Ceased WO2002055544A2 (fr) 2000-12-23 2001-12-21 Fractions de fixation de la fibrine qui conviennent comme agents d'imagerie

Country Status (5)

Country Link
EP (1) EP1348026A2 (fr)
JP (1) JP3991086B2 (fr)
AU (1) AU2002248222B2 (fr)
CA (1) CA2432474C (fr)
WO (1) WO2002055544A2 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005079863A1 (fr) * 2004-02-25 2005-09-01 Astellas Pharma Inc. Produit de contraste pour la formation d'un thrombus
WO2005029066A3 (fr) * 2003-05-22 2005-09-29 Agilent Technologies Inc Marqueurs de diagnostic et cibles pharmacologiques utilises dans l'insuffisance cardiaque, et reactifs connexes et leurs procedes d'utilisation
EP1443953A4 (fr) * 2001-10-16 2005-11-23 Epix Pharm Inc Detection et traitement de lesions intravasculaires
JP2006524034A (ja) * 2002-12-20 2006-10-26 アムジェン インコーポレイテッド ミオスタチンを阻害する結合剤
WO2008071679A1 (fr) 2006-12-11 2008-06-19 Bracco Imaging Spa Conjugués peptidiques se liant à la fibrine pour des applications de diagnostic et thérapeutiques
ITFI20080173A1 (it) * 2008-09-05 2010-03-06 Univ Firenze Complessi di manganese e cobalto, loro preparazione ed uso
US7749485B2 (en) 2004-06-03 2010-07-06 Bracco Research S.A. Liposomal assembly for therapeutic and/or diagnostic use
US8293214B2 (en) 2006-12-19 2012-10-23 Bracco Suisse S.A. Targeting and therapeutic compounds and gas-filled microvesicles comprising said compounds
US8815804B2 (en) 2006-02-06 2014-08-26 Sanford-Burnham Medical Research Institute Methods and compositions related to targeting tumors and wounds
US9192685B2 (en) 2008-10-07 2015-11-24 Bracco Suisse S.A. Targeting construct comprising anti-polymer antibody and contrast/therapeutic agents binding to the same
US9248204B2 (en) 2004-08-18 2016-02-02 Bracco Suisse S.A. Gas-filled microvesicles composition for contrast imaging
US9364569B2 (en) 2003-02-04 2016-06-14 Bracco Suisse S.A. Ultrasound contrast agents and process for the preparation thereof
US9375397B2 (en) 2005-04-18 2016-06-28 Bracco Suisse S.A. Composition comprising gas-filled microcapsules for ultrasound mediated delivery
US9446156B2 (en) 2006-09-05 2016-09-20 Bracco Suisse S.A. Gas-filled microvesicles with polymer-modified lipids
US9750821B2 (en) 2003-12-22 2017-09-05 Bracco Suisse S.A. Gas-filled microvesicle assembly for contrast imaging
US10010630B2 (en) 2012-12-21 2018-07-03 Bracco Suisse S.A. Gas-filled microvesicles
CN109127131A (zh) * 2018-07-18 2019-01-04 沛县育龙粮油工贸有限公司 一种高效重金属污染大米的清洗方法
WO2020229642A1 (fr) 2019-05-15 2020-11-19 Bracco Suisse Sa Produit lyophilisé et suspension de microvésicules remplies de gaz
US11717570B2 (en) 2019-05-15 2023-08-08 Bracco Suisse Sa Gas-filled microvesicles
WO2025073838A1 (fr) 2023-10-04 2025-04-10 Bracco Suisse Sa Procédé de lyophilisation

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010514839A (ja) * 2007-01-03 2010-05-06 バーナム インスティテュート フォー メディカル リサーチ クロット結合化合物に関連する方法および組成物
KR101474063B1 (ko) 2012-05-23 2014-12-19 동국대학교 산학협력단 피브린 표적 펩타이드 서열이 결합된 글라이콜 키토산-금 나노입자를 포함하는 혈전 탐지용 ｃｔ 조영제
MX2021005089A (es) * 2021-04-30 2022-11-01 Instituto Nac De Investigaciones Nucleares Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025241A1 (fr) 1992-06-13 1993-12-23 Schering Aktiengesellschaft Utilisation de microcapsules comme agents de contraste pour la sonographie doppler en couleurs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02504472A (ja) * 1988-06-03 1990-12-20 セルテック　リミテッド ハイブリッド蛋白
US5364612A (en) * 1991-05-06 1994-11-15 Immunomedics, Inc. Detection of cardiovascular lesions
TWI290146B (en) * 1999-07-29 2007-11-21 Dyax Corp Binding moieties for fibrin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025241A1 (fr) 1992-06-13 1993-12-23 Schering Aktiengesellschaft Utilisation de microcapsules comme agents de contraste pour la sonographie doppler en couleurs

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1443953A4 (fr) * 2001-10-16 2005-11-23 Epix Pharm Inc Detection et traitement de lesions intravasculaires
JP2006524034A (ja) * 2002-12-20 2006-10-26 アムジェン インコーポレイテッド ミオスタチンを阻害する結合剤
JP2010193888A (ja) * 2002-12-20 2010-09-09 Amgen Inc ミオスタチンを阻害する結合剤
JP2013048622A (ja) * 2002-12-20 2013-03-14 Amgen Inc ミオスタチンを阻害する結合剤
US9364569B2 (en) 2003-02-04 2016-06-14 Bracco Suisse S.A. Ultrasound contrast agents and process for the preparation thereof
WO2005029066A3 (fr) * 2003-05-22 2005-09-29 Agilent Technologies Inc Marqueurs de diagnostic et cibles pharmacologiques utilises dans l'insuffisance cardiaque, et reactifs connexes et leurs procedes d'utilisation
US9750821B2 (en) 2003-12-22 2017-09-05 Bracco Suisse S.A. Gas-filled microvesicle assembly for contrast imaging
WO2005079863A1 (fr) * 2004-02-25 2005-09-01 Astellas Pharma Inc. Produit de contraste pour la formation d'un thrombus
US7749485B2 (en) 2004-06-03 2010-07-06 Bracco Research S.A. Liposomal assembly for therapeutic and/or diagnostic use
US10076580B2 (en) 2004-08-18 2018-09-18 Bracco Suisse S.A. Gas-filled microvesicles composition for contrast imaging
US9248204B2 (en) 2004-08-18 2016-02-02 Bracco Suisse S.A. Gas-filled microvesicles composition for contrast imaging
US9375397B2 (en) 2005-04-18 2016-06-28 Bracco Suisse S.A. Composition comprising gas-filled microcapsules for ultrasound mediated delivery
US8815804B2 (en) 2006-02-06 2014-08-26 Sanford-Burnham Medical Research Institute Methods and compositions related to targeting tumors and wounds
US9522198B2 (en) 2006-02-06 2016-12-20 Sanford-Burnham Medical Research Institute Methods and compositions related to targeting tumors and wounds
US9446156B2 (en) 2006-09-05 2016-09-20 Bracco Suisse S.A. Gas-filled microvesicles with polymer-modified lipids
US9333272B2 (en) 2006-12-11 2016-05-10 Bracco Imaging Spa Fibrin binding peptide conjugates for diagnostic and therapeutic applications
US8466107B2 (en) 2006-12-11 2013-06-18 Bracco Imaging Spa Fibrin-binding peptides and conjugates thereof
CN101573143B (zh) * 2006-12-11 2013-04-24 伯拉考成像股份公司 纤维蛋白结合肽及其缀合体
US8278274B2 (en) 2006-12-11 2012-10-02 Bracco Imaging Spa Fibrin-binding peptides and conjugates thereof
EP2111237A4 (fr) * 2006-12-11 2011-04-13 Bracco Imaging Spa Peptides se fixant à la fibrine, et conjugués correspondants
WO2008071679A1 (fr) 2006-12-11 2008-06-19 Bracco Imaging Spa Conjugués peptidiques se liant à la fibrine pour des applications de diagnostic et thérapeutiques
US8293214B2 (en) 2006-12-19 2012-10-23 Bracco Suisse S.A. Targeting and therapeutic compounds and gas-filled microvesicles comprising said compounds
WO2010026545A1 (fr) 2008-09-05 2010-03-11 Universita' Degli Studi Di Firenze Complexes de manganèse et de cobalt, leur synthèse et leur application
ITFI20080173A1 (it) * 2008-09-05 2010-03-06 Univ Firenze Complessi di manganese e cobalto, loro preparazione ed uso
US9192685B2 (en) 2008-10-07 2015-11-24 Bracco Suisse S.A. Targeting construct comprising anti-polymer antibody and contrast/therapeutic agents binding to the same
US10010630B2 (en) 2012-12-21 2018-07-03 Bracco Suisse S.A. Gas-filled microvesicles
CN109127131A (zh) * 2018-07-18 2019-01-04 沛县育龙粮油工贸有限公司 一种高效重金属污染大米的清洗方法
WO2020229642A1 (fr) 2019-05-15 2020-11-19 Bracco Suisse Sa Produit lyophilisé et suspension de microvésicules remplies de gaz
US11426352B2 (en) 2019-05-15 2022-08-30 Bracco Suisse Sa Freeze-dried product and gas-filled microvesicles suspension
US11717570B2 (en) 2019-05-15 2023-08-08 Bracco Suisse Sa Gas-filled microvesicles
US11723869B2 (en) 2019-05-15 2023-08-15 Bracco Suisse Sa Freeze-dried product and gas-filled microvesicles suspension
WO2025073838A1 (fr) 2023-10-04 2025-04-10 Bracco Suisse Sa Procédé de lyophilisation

Also Published As

Publication number Publication date
CA2432474A1 (fr) 2002-07-18
JP3991086B2 (ja) 2007-10-17
CA2432474C (fr) 2012-06-26
AU2002248222B2 (en) 2006-04-27
WO2002055544A3 (fr) 2003-03-27
JP2004523514A (ja) 2004-08-05
EP1348026A2 (fr) 2003-10-01

Similar Documents

Publication Publication Date Title
US6984373B2 (en) Fibrin binding moieties useful as imaging agents
AU2004201485B2 (en) Binding moieties for fibrin
CA2432474C (fr) Fractions de fixation de la fibrine qui conviennent comme agents d'imagerie
AU2002248222A1 (en) Fibrin binding polypeptides useful inter alia in medical imaging processes
CA2517939C (fr) Peptides presentant une fixation specifique avec le recepteur de hgf (cmet) et ses utilisations
US9333272B2 (en) Fibrin binding peptide conjugates for diagnostic and therapeutic applications
AU2012241087B2 (en) Peptides that specifically bind HGF receptor (cMet) and uses thereof
AU2015201413B2 (en) Peptides that specifically bind HGF receptor (cMet) and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002248222

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002556612

Country of ref document: JP

Ref document number: 2432474

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001997103

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001997103

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642